Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for miroliverELAP in Acute liver failure. The expected timing is based on the latest available company guidance and may change.
6/24/25- Ph1 study began in 2024, with the first external liver support treatment using a bioengineered liver performed on ALF patient in June 2025. 01/26/26:- Met survival endpoint with no unexpected serious safety issues. Full results and publication in H2 2026. 04/08/26:- FDA granted RMAT designation. Full Phase 1 results publication still planned H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.